<abstract xmlns="http://www.w3.org/1999/xhtml">

This manuscript reviews evidences underlying the estimation of risk of malignancy enhancement of advanced aggressive cancers as a result of the gamma radiation emitted by tracers used in PET diagnostics. We conclude that among many cancers, such a phenomenon likely occurs, particularly in tumor cells with an aggressive biology in the advanced stages of their development, <italic>e.g</italic>. prostate cancer, melanoma and colorectal cancer. Moreover, we surmise based on gathered evidence that fluorine -18 (18F) labeled pharmaceuticals (18F-deoxyglucose and 18F-choline), commonly used in positron emission tomography (PET) can lead to malignancy enhancement of diagnosed cancer, manifesting as accelerated infiltration of the neighboring tissue, accelerated metastasis and/or radio- and chemotherapy resistance. In this review, some suggestions on future studies verifying this concept are also proposed. If our concerns are justified, it might be appropriate in the future to consider this assumption at the stage of deciding whether to undertake PET monitoring in some patients with advanced aggressive cancer.
</abstract>

This manuscript reviews evidences underlying the estimation of risk of malignancy enhancement of advanced aggressive cancers as a result of the gamma radiation emitted by tracers used in PET diagnostics. We conclude that among many cancers, such a phenomenon likely occurs, particularly in tumor cells with an aggressive biology in the advanced stages of their development, e.g. prostate cancer, melanoma and colorectal cancer. Moreover, we surmise based on gathered evidence that fluorine -18 (18F) labeled pharmaceuticals (18F-deoxyglucose and 18F-choline), commonly used in positron emission tomography (PET) can lead to malignancy enhancement of diagnosed cancer, manifesting as accelerated infiltration of the neighboring tissue, accelerated metastasis and/or radio- and chemotherapy resistance. In this review, some suggestions on future studies verifying this concept are also proposed. If our concerns are justified, it might be appropriate in the future to consider this assumption at the stage of deciding whether to undertake PET monitoring in some patients with advanced aggressive cancer.

The risk of increasing tumor malignancy after PET diagnosis

Department of Biological Bases of Animal Production

Department of Pneumology, Oncology and Allergology

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"The risk of increasing tumor malignancy after PET diagnosis"}

This manuscript reviews evidences underlying the estimation of risk of malignancy enhancement of advanced aggressive cancers as a result of the gamma radiation...

The risk of increasing tumor malignancy after PET diagnosis

Published Online: Jul 28, 2022

Page range: 34 - 40

Received: Jun 15, 2021

Accepted: Dec 12, 2021

DOI: https://doi.org/10.2478/cipms-2022-0007

Keywords
gamma radiation, tumor malignancy, positron emission tomography

© 2022 Agnieszka Korga-Plewko et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

The risk of increasing tumor malignancy after PET diagnosis

Published Online: Jul 28, 2022

Page range: 34 - 40

Received: Jun 15, 2021

Accepted: Dec 12, 2021

DOI: https://doi.org/10.2478/cipms-2022-0007

Keywordsgamma radiation, tumor malignancy, positron emission tomography

© 2022 Agnieszka Korga-Plewko et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Keywords
gamma radiation, tumor malignancy, positron emission tomography